Champions Oncology, Inc. (CSBR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Champions Oncology, Inc. (CSBR) trades at $5.18 with AI Score 26/100 (Grade F). Champions Oncology, Inc. personalizes oncology drug development through its Tumorgraft Technology Platform. Market cap: $72.0M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for CSBR: CSBR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSBR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSBR: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Champions Oncology, Inc. (CSBR) Healthcare & Pipeline Overview
Champions Oncology, Inc. develops and sells technology solutions and products for personalized oncology drug development in the United States, leveraging its Tumorgraft Technology Platform and Lumin Bioinformatics platform to serve pharmaceutical and biotechnology companies, while operating in a competitive biotechnology landscape.
What Is the Investment Thesis for CSBR?
Champions Oncology, Inc. presents a focused investment opportunity within the personalized oncology space. The company's Tumorgraft Technology Platform and Translational Oncology Solutions offer potential for growth, driven by increasing demand for personalized cancer treatments and drug development tools. While the company's market capitalization is $0.08 billion, potential investors may want to evaluate the company's negative profit margin of -3.9% and the competitive landscape. Key growth catalysts include expanding partnerships with pharmaceutical companies and increasing adoption of the Lumin Bioinformatics platform. The company's beta of 0.40 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
CSBR Key Highlights
Market capitalization of $72.0M, reflecting its position as a smaller player in the biotechnology industry.
- Gross margin of 43.4%, indicating the profitability of its core services and products.
- Negative profit margin of -3.9%, highlighting the need for improved operational efficiency and cost management.
- Beta of 0.40, suggesting lower volatility compared to the broader market.
- Focus on personalized oncology drug development, aligning with the growing trend towards precision medicine.
Who Are CSBR's Competitors?
CSBR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSBR's Key Strengths?
Proprietary Tumorgraft Technology Platform
- Expertise in personalized oncology drug development
- Lumin Bioinformatics platform
- Established presence in the United States
What Are CSBR's Weaknesses?
Negative profit margin
- Smaller market capitalization compared to competitors
- Limited geographic reach
- Dependence on partnerships with pharmaceutical companies
What Could Drive CSBR Stock Higher?
CSBR catalyst: Potential new partnerships with major pharmaceutical companies to utilize Champions Oncology's Tumorgraft Technology Platform in drug development.
- Increasing adoption and subscription rates for the Lumin Bioinformatics platform among research institutions and pharmaceutical companies.
- Expansion into new international markets, particularly in Europe and Asia, to broaden the company's customer base.
- Development and validation of new Tumorgraft models for additional cancer types, enhancing the platform's utility and market appeal.
What Are the Key Risks for CSBR?
Financial-distress signal — its Altman Z-Score of -0.30 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-58.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies and contract research organizations (CROs) with greater resources and established market presence.
- Regulatory changes or delays in drug approval processes that could impact the demand for Champions Oncology's services.
- Dependence on securing and maintaining partnerships with pharmaceutical companies for revenue generation.
- Technological advancements that could render the Tumorgraft Technology Platform or Lumin Bioinformatics platform obsolete.
- Negative profit margin and the need to achieve profitability through improved operational efficiency and cost management.
What Are the Growth Opportunities for CSBR?
- Expanding partnerships with pharmaceutical companies: Champions Oncology can leverage its Tumorgraft Technology Platform to secure more partnerships with pharmaceutical companies seeking personalized drug development solutions. The market for oncology drug development is estimated to reach $200 billion by 2030, presenting a significant opportunity for Champions Oncology to increase its revenue through strategic collaborations. This growth opportunity is ongoing.
- Increasing adoption of the Lumin Bioinformatics platform: The Lumin Bioinformatics platform offers a recurring revenue stream through annual subscriptions. By enhancing the platform's features and expanding its database, Champions Oncology can attract more subscribers and increase its market share. The bioinformatics market is projected to reach $25 billion by 2028, providing a substantial growth opportunity. This growth opportunity is ongoing.
- Geographic expansion into international markets: Champions Oncology can expand its operations into international markets, such as Europe and Asia, to tap into the growing demand for personalized oncology solutions. The global market for personalized medicine is expected to reach $3.5 trillion by 2030, offering a significant opportunity for Champions Oncology to diversify its revenue streams. This growth opportunity is upcoming.
- Development of new Tumorgraft models for various cancer types: Champions Oncology can invest in developing new Tumorgraft models for a wider range of cancer types, expanding its addressable market and attracting more customers. The market for cancer modeling is projected to reach $5 billion by 2027, presenting a substantial growth opportunity for Champions Oncology. This growth opportunity is ongoing.
- Integration of artificial intelligence and machine learning into its platform: Champions Oncology can integrate AI and machine learning technologies into its Tumorgraft Technology Platform and Lumin Bioinformatics platform to enhance their capabilities and provide more insights to customers. The market for AI in drug discovery is expected to reach $4 billion by 2028, offering a significant opportunity for Champions Oncology to improve its offerings and attract more customers. This growth opportunity is upcoming.
What Threats Does CSBR Face?
- Competition from larger pharmaceutical companies and CROs
- Regulatory changes affecting drug development
- Technological advancements rendering existing platforms obsolete
- Economic downturn impacting research and development spending
What Are CSBR's Competitive Advantages?
- Proprietary Tumorgraft Technology Platform.
- Specialized expertise in personalized oncology drug development.
- Lumin Bioinformatics platform with comprehensive research and clinical data.
What Does CSBR Do?
Champions Oncology, Inc., incorporated in 1985 and headquartered in Hackensack, New Jersey, is a biotechnology company focused on developing and selling technology solutions and products aimed at personalizing the development and use of oncology drugs. The company's core offering is its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice to provide personalized cancer care insights. This platform allows for the study of drug efficacy and personalized treatment strategies. In addition to its Tumorgraft Technology Platform, Champions Oncology offers Translational Oncology Solutions, which utilize the platform to assist pharmaceutical and biotechnology companies with their drug development processes. These solutions help companies optimize their drug candidates and accelerate the development timeline. The company also provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, sold on an annual subscription basis. Champions Oncology markets its products and services through various channels, including the internet, word of mouth, and a dedicated sales force, targeting patients, physicians, and pharmaceutical companies. Formerly known as Champions Biotechnology, Inc., the company changed its name to Champions Oncology, Inc. in April 2011, reflecting its strategic focus on oncology solutions.
What Products and Services Does CSBR Offer?
- Develop and sell technology solutions for personalized oncology drug development.
- Offer the Tumorgraft Technology Platform for personalized cancer care.
- Provide Translational Oncology Solutions to assist pharmaceutical and biotechnology companies.
- Offer the Lumin Bioinformatics platform for research and clinical data analysis.
- Market products through internet, word of mouth, and a sales force.
- Focus on personalizing the development and use of oncology drugs.
How Does CSBR Make Money?
- Selling access to the Tumorgraft Technology Platform.
- Providing Translational Oncology Solutions to pharmaceutical and biotechnology companies.
- Offering annual subscriptions to the Lumin Bioinformatics platform.
What Industry Does CSBR Operate In?
Champions Oncology operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The market for personalized oncology treatments and drug development tools is growing, driven by advancements in genomics and the increasing prevalence of cancer. Companies like Champions Oncology face competition from larger pharmaceutical companies and specialized CROs (Contract Research Organizations). The industry is also influenced by trends such as the adoption of artificial intelligence and machine learning in drug discovery and development.
Who Are CSBR's Key Customers?
- Pharmaceutical companies seeking personalized drug development solutions.
- Biotechnology companies requiring assistance with their drug development processes.
- Patients and physicians seeking personalized cancer care insights.
Forward Outlook
Wall Street analysts project Champions Oncology, Inc. revenue of about $58.5M for fiscal 2026, with EPS near $0.12.
Earnings Track Record
Champions Oncology, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 478.1% above estimates on average.
Financial Health
Champions Oncology, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.30 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Champions Oncology, Inc. stands at -58.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Champions Oncology, Inc. (CSBR) Valuation Context
Valued at $72.0M, CSBR is classified as a micro-cap stock. Relative to its peer group, CSBR's quantitative score of 26/100 is below the peer average of 76/100.
CSBR Revenue & Earnings Trend
In Q2 2026, CSBR generated $13.8M in top-line revenue, marking a sequential decrease of 16.4%. The company recorded a net loss of $729K, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CSBR averaged $-0.02 in diluted EPS.
Company Profile
Champions Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hackensack, US. The company is led by CEO Robert Brainin. CSBR has traded publicly since 2007.
CSBR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Proprietary Tumorgraft Technology Platform
- Expertise in personalized oncology drug development
- Lumin Bioinformatics platform
- Established presence in the United States
Bear Case
- Negative profit margin
- Smaller market capitalization compared to competitors
- Limited geographic reach
- Dependence on partnerships with pharmaceutical companies
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $14M | -$729,000 | -$0.05 |
| Q1 2026 | $17M | -$279,000 | -$0.02 |
| Q4 2025 | $15M | $299,000 | $0.02 |
| Q3 2025 | $14M | -$466,000 | -$0.03 |
Based on FMP financials and quantitative analysis
CSBR Latest News
No recent news available for CSBR.
CSBR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSBR.
Price Targets
Wall Street price target analysis for CSBR.
CSBR MoonshotScore
What does this score mean?
The MoonshotScore rates CSBR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert Brainin
CEO
Robert Brainin serves as the CEO of Champions Oncology, Inc., managing a team of 210 employees. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions in companies focused on drug development and personalized medicine. Brainin's expertise lies in strategic planning, business development, and commercialization of innovative healthcare solutions. He is responsible for driving Champions Oncology's growth and expanding its market presence.
Track Record: Under Robert Brainin's leadership, Champions Oncology has focused on expanding its Tumorgraft Technology Platform and Lumin Bioinformatics platform. He has overseen strategic partnerships with pharmaceutical companies and driven the company's focus on personalized oncology drug development. Key milestones include expanding the company's service offerings and increasing its customer base. His leadership has been instrumental in navigating the competitive biotechnology landscape.
CSBR Healthcare Stock FAQ
What does the AI Score mean for CSBR?
CSBR holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Champions Oncology, Inc. personalizes oncology drug development through its Tumorgraft Technology Platform. The company offers translational oncology solutions and a bioinformatics platform …
What does Champions Oncology, Inc. do?
Champions Oncology, Inc. is a biotechnology company that develops and sells technology solutions and products to personalize oncology drug development. Its core offering is the Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice to study drug efficacy and personalize treatment strategies.
What do analysts say about CSBR stock?
Analyst coverage of Champions Oncology, Inc. (CSBR) is limited, reflecting its smaller market capitalization within the biotechnology sector. Key valuation metrics, such as price-to-earnings ratio, are less relevant due to the company's negative profit margin. Growth considerations center on the company's ability to expand its partnerships with pharmaceutical companies, increase adoption of the Lumin Bioinformatics platform, and achieve profitability.
What are the main risks for CSBR?
Champions Oncology, Inc. faces several key risks, including competition from larger pharmaceutical companies and CROs with greater resources, regulatory changes affecting drug development, and technological advancements that could render its platforms obsolete. The company's dependence on securing and maintaining partnerships with pharmaceutical companies for revenue generation is also a significant risk.
What are the key factors to evaluate for CSBR?
Champions Oncology, Inc. (CSBR) holds an AI score of 26/100 (low). presents a focused investment opportunity within the personalized oncology space. Not financial advice.
How frequently does CSBR data refresh on this page?
CSBR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CSBR's recent stock price performance?
Champions Oncology, Inc. (CSBR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Tumorgraft Technology Platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSBR overvalued or undervalued right now?
Champions Oncology, Inc. (CSBR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CSBR before investing?
Before investing in Champions Oncology, Inc. (CSBR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Competitive landscape analysis is based on publicly available information.
- Growth opportunities are based on market research and industry trends.